VMC Members[close]

Login

Not yet a member?

Stay up to date with
the latest health news




Are you a Health Professional?

Read more detailed and referenced information written by Australian health professionals, make sure you select health professional in the signup form!

Cancer drug helps purge hidden HIV virus

A team of researchers at the University of North Carolina at Chapel Hill have successfully flushed latent HIV infection from hiding, with a drug used to treat certain types of lymphoma.

Tackling latent HIV in the immune system is critical to finding a cure for AIDS.

The results were presented at the 19th Conference on Retroviruses and Opportunistic Infections in Seattle, Washington.

While current antiretroviral therapies can very effectively control virus levels, they can never fully eliminate the virus from the cells and tissues it has infected. 

“Lifelong use of antiretroviral therapy is problematic for many reasons, not least among them are drug resistance, side effects, and cost,” said David Margolis, MD, professor of medicine, microbiology and immunology, and epidemiology at the University of North Carolina at Chapel Hill. “We need to employ better long-term strategies, including a cure.”

Margolis’ new study is the first to demonstrate that the biological mechanism that keeps the HIV virus hidden and unreachable by current antiviral therapies can be targeted and interrupted in humans, providing new hope for a strategy to eradicate HIV completely.

In a clinical trial, six HIV-infected men who were medically stable on anti-AIDS drugs, received vorinostat, an oncology drug. Recent studies by Margolis and others have shown that vorinostat also attacks the enzymes that keep HIV hiding in certain CD4+ T cells, specialised immune system cells that the virus uses to replicate. Within hours of receiving the vorinostat, all six patients had a significant increase in HIV RNA in these cells, evidence that the virus was being forced out of its hiding place.

“This proves for the first time that there are ways to specifically treat viral latency, the first step towards curing HIV infection,” said Margolis, who led the study.  “It shows that this class of drugs, HDAC inhibitors, can attack persistent virus.  Vorinostat may not be the magic bullet, but this success shows us a new way to test drugs to target latency, and suggests that we can build a path that may lead to a cure.” 


(Source: University of North Carolina)


calendar icon Article Date: 21/3/2012

 

Related Diseases

 

Related Articles:


Connect

Sign up for free newsletter Sign up for free newsletters
News RSS feeds Subscribe to RSS feeds
Discuss on Forum Discuss on Forum
share this page with others

 

Article Comments

Add your comment to this article





 Change Code


 Enter the above security Code

User-generated Content Guidelines

Rate this article

Current Sponsors
About Virtualmedicalcentre.com

Virtual Medical Centre

Australia’s leading source for trustworthy medical information written by health professionals.

Please be aware that we do not give advice on your individual medical condition,
if you want advice please see your treating physician.

Virtual Medical Centre © 2002 - 2013 | Privacy Policy Last updated 19 May 2013

Parenting information is available at Parenthub.com.au

^ Back to Top
 
Partners and Accreditations
This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.
Health insite MindHealth Connect Pregnancy Birth and Baby
PANDORA is a digital archive dedicated to the preservation of and long term access to Australian online electronic publications of national significance Parenthub.com.au for parenting information
For banner advertising
Multi Channel Network
Website and videos by
Titan Web
Titan Web Clients
Web Design Perth
close

Join our FREE fortnightly health newsletter!

Simply enter your email address below:


No, Thanks!

Virtual Medical Centre respects your privacy.
You can unsubscribe from the newsletter at any time.
Please read our Terms of Use and Privacy Policy.

Health Professionals signup for the professional newsletter!

Are your a health professional?
Sign up to receive our dedicated newsletter for health professionals